annual cash & cash equivalents:
$173.73M-$39.85M(-18.66%)Summary
- As of today (July 5, 2025), RARE annual cash & cash equivalents is $173.73 million, with the most recent change of -$39.85 million (-18.66%) on December 31, 2024.
- During the last 3 years, RARE annual cash & cash equivalents has fallen by -$133.85 million (-43.52%).
- RARE annual cash & cash equivalents is now -75.65% below its all-time high of $713.53 million, reached on December 31, 2020.
Performance
RARE Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$127.06M-$46.67M(-26.87%)Summary
- As of today (July 5, 2025), RARE quarterly cash & cash equivalents is $127.06 million, with the most recent change of -$46.67 million (-26.87%) on March 31, 2025.
- Over the past year, RARE quarterly cash & cash equivalents has increased by +$14.80 million (+13.19%).
- RARE quarterly cash & cash equivalents is now -82.19% below its all-time high of $713.53 million, reached on December 31, 2020.
Performance
RARE quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
RARE Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -18.7% | +13.2% |
| 3 y3 years | -43.5% | -17.5% |
| 5 y5 years | -59.9% | -57.4% |
RARE Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -43.5% | +30.7% | -73.6% | +75.1% |
| 5 y | 5-year | -75.7% | +30.7% | -82.2% | +75.1% |
| alltime | all time | -75.7% | +2239.2% | -82.2% | +2000.4% |
RARE Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $127.06M(-26.9%) |
| Dec 2024 | $173.73M(-18.7%) | $173.73M(+15.3%) |
| Sep 2024 | - | $150.62M(-68.7%) |
| Jun 2024 | - | $480.69M(+328.2%) |
| Mar 2024 | - | $112.25M(-47.4%) |
| Dec 2023 | $213.58M(+60.7%) | $213.58M(+194.3%) |
| Sep 2023 | - | $72.58M(-28.9%) |
| Jun 2023 | - | $102.06M(+19.0%) |
| Mar 2023 | - | $85.77M(-35.5%) |
| Dec 2022 | $132.94M(-56.8%) | $132.94M(-66.1%) |
| Sep 2022 | - | $391.65M(+145.0%) |
| Jun 2022 | - | $159.87M(+3.8%) |
| Mar 2022 | - | $153.99M(-49.9%) |
| Dec 2021 | $307.58M(-56.9%) | $307.58M(+55.7%) |
| Sep 2021 | - | $197.54M(-32.1%) |
| Jun 2021 | - | $290.88M(-24.2%) |
| Mar 2021 | - | $383.79M(-46.2%) |
| Dec 2020 | $713.53M(+64.6%) | $713.53M(+261.3%) |
| Sep 2020 | - | $197.49M(-41.2%) |
| Jun 2020 | - | $335.64M(+12.6%) |
| Mar 2020 | - | $298.19M(-31.2%) |
| Dec 2019 | $433.58M | $433.58M(+253.7%) |
| Sep 2019 | - | $122.58M(-6.7%) |
| Jun 2019 | - | $131.34M(-51.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2019 | - | $269.71M(+137.8%) |
| Dec 2018 | $113.43M(+12.9%) | $113.43M(+36.7%) |
| Sep 2018 | - | $82.96M(-25.2%) |
| Jun 2018 | - | $110.85M(-51.1%) |
| Mar 2018 | - | $226.73M(+125.6%) |
| Dec 2017 | $100.49M(-37.6%) | $100.49M(+66.4%) |
| Sep 2017 | - | $60.41M(-33.4%) |
| Jun 2017 | - | $90.75M(-43.1%) |
| Mar 2017 | - | $159.50M(-1.0%) |
| Dec 2016 | $161.12M(+72.2%) | $161.12M(+13.2%) |
| Sep 2016 | - | $142.28M(+158.4%) |
| Jun 2016 | - | $55.07M(-22.2%) |
| Mar 2016 | - | $70.76M(-24.4%) |
| Dec 2015 | $93.57M(+284.7%) | $93.57M(-43.9%) |
| Sep 2015 | - | $166.69M(+218.4%) |
| Jun 2015 | - | $52.35M(-70.6%) |
| Mar 2015 | - | $178.04M(+632.0%) |
| Dec 2014 | $24.32M(+227.5%) | $24.32M(-54.4%) |
| Sep 2014 | - | $53.39M(+205.9%) |
| Jun 2014 | - | $17.45M(-68.5%) |
| Mar 2014 | - | $55.45M(+646.6%) |
| Dec 2013 | $7.43M(-91.4%) | $7.43M(+22.8%) |
| Sep 2013 | - | $6.05M(-93.0%) |
| Dec 2012 | $86.19M(+709.7%) | $86.19M |
| Dec 2011 | $10.64M | - |
FAQ
- What is Ultragenyx Pharmaceutical annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical annual cash & cash equivalents year-on-year change?
- What is Ultragenyx Pharmaceutical quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical quarterly cash & cash equivalents year-on-year change?
What is Ultragenyx Pharmaceutical annual cash & cash equivalents?
The current annual cash & cash equivalents of RARE is $173.73M
What is the all time high annual cash & cash equivalents for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high annual cash & cash equivalents is $713.53M
What is Ultragenyx Pharmaceutical annual cash & cash equivalents year-on-year change?
Over the past year, RARE annual cash & cash equivalents has changed by -$39.85M (-18.66%)
What is Ultragenyx Pharmaceutical quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of RARE is $127.06M
What is the all time high quarterly cash & cash equivalents for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high quarterly cash & cash equivalents is $713.53M
What is Ultragenyx Pharmaceutical quarterly cash & cash equivalents year-on-year change?
Over the past year, RARE quarterly cash & cash equivalents has changed by +$14.80M (+13.19%)